<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00310024</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02693</org_study_id>
    <secondary_id>GCC 0514</secondary_id>
    <secondary_id>N01CM62204</secondary_id>
    <secondary_id>CDR0000466109</secondary_id>
    <nct_id>NCT00310024</nct_id>
  </id_info>
  <brief_title>Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase I Study of SAHA in Combination With Bortezomib in Relapsed and Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of vorinostat when given&#xD;
      together with bortezomib in treating patients with relapsed or refractory multiple myeloma.&#xD;
      Vorinostat and bortezomib may stop the growth of cancer cells by blocking some of the enzymes&#xD;
      needed for cell growth. Giving vorinostat together with bortezomib may kill more cancer cells&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose (MTD) of vorinostat (SAHA) when given together with&#xD;
      bortezomib in patients with relapsed or refractory multiple myeloma (MM).&#xD;
&#xD;
      II. Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine whether giving SAHA together with bortezomib inhibits histone deacetylation in&#xD;
      normal cells (buccal mucosal cells and/or peripheral blood monocytes) as well as in MM cells.&#xD;
&#xD;
      II. Evaluate the effect of dexamethasone when given together with SAHA and bortezomib.&#xD;
&#xD;
      III. Explore molecular mechanisms involved in apoptosis in MM mediated by SAHA and&#xD;
      bortezomib.&#xD;
&#xD;
      IV. Correlate change of histone acetylation with clinical outcome in patients treated with&#xD;
      this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose escalation study of vorinostat (SAHA).&#xD;
&#xD;
      Patients receive bortezomib IV on days 1, 4, 8, and 11 followed by oral SAHA twice daily on&#xD;
      days 4-11. Beginning in course 3, some patients may receive low-dose oral dexamethasone on&#xD;
      days 4-8. Treatment repeats every 21 days for up to 8 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6&#xD;
      patients experience dose-limiting toxicity. An additional cohort of 10 patients receive&#xD;
      treatment at the MTD.&#xD;
&#xD;
      Patients undergo blood collection and tumor biopsies periodically during study for&#xD;
      pharmacologic and biomarker correlative studies.&#xD;
&#xD;
      After completion of study treatment, patients are followed at least once a month.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of SAHA in combination with bortezomib determined by dose-limiting toxicities</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inhibition of histone deacetylation</measure>
    <time_frame>Up to 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>The estimates and the corresponding 90% confidence intervals will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival (disease specific and overall)</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>Will be estimated using the Kaplan-Meir method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Refractory Multiple Myeloma</condition>
  <condition>Stage I Multiple Myeloma</condition>
  <condition>Stage II Multiple Myeloma</condition>
  <condition>Stage III Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Treatment (vorinostat, bortezomib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bortezomib IV on days 1, 4, 8, and 11 followed by oral SAHA twice daily on days 4-11. Beginning in course 3, some patients may receive low-dose oral dexamethasone on days 4-8. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional cohort of 10 patients receive treatment at the MTD.&#xD;
Patients undergo blood collection and tumor biopsies periodically during study for pharmacologic and biomarker correlative studies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (vorinostat, bortezomib)</arm_group_label>
    <other_name>LDP 341</other_name>
    <other_name>MLN341</other_name>
    <other_name>VELCADE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vorinostat</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (vorinostat, bortezomib)</arm_group_label>
    <other_name>L-001079038</other_name>
    <other_name>SAHA</other_name>
    <other_name>suberoylanilide hydroxamic acid</other_name>
    <other_name>Zolinza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (vorinostat, bortezomib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (vorinostat, bortezomib)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically and clinically confirmed multiple myeloma&#xD;
&#xD;
               -  Relapsed or refractory disease after prior chemotherapy or transplantation*&#xD;
&#xD;
          -  Measurable disease, defined by quantitative immunoglobulin levels in serum and/or&#xD;
             urine and bone marrow plasmacytosis&#xD;
&#xD;
               -  Non-secretory disease allowed provided MRI or positron emission tomography or CT&#xD;
                  scan can accurately measure at least one plasmacytoma lesion&#xD;
&#xD;
          -  No known CNS involvement&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm³ (unless myelosuppression is secondary to bone&#xD;
             marrow plasmacytosis [&gt; 80% involvement])&#xD;
&#xD;
          -  Platelet count ≥ 50,000/mm³ (unless myelosuppression is secondary to bone marrow&#xD;
             plasmacytosis [&gt; 80% involvement])&#xD;
&#xD;
          -  Bilirubin ≤ 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 2 times ULN&#xD;
&#xD;
          -  Creatinine &lt; 2 mg/dL OR creatinine clearance &gt; 40 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Able to swallow pills&#xD;
&#xD;
          -  Patients with a history of seizures are eligible provided seizures are under adequate&#xD;
             control with non-enzyme inducing anticonvulsant medication&#xD;
&#xD;
          -  No history of allergic reactions attributed to study agents&#xD;
&#xD;
          -  No sensory or motor neuropathy ≥ grade II&#xD;
&#xD;
          -  No uncontrolled current illness including, but not limited to, the following:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Psychiatric illness or social situation that would limit study compliance&#xD;
&#xD;
          -  No grade 3 QT prolongation (i.e., &gt; 500 msec) at baseline&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior bortezomib allowed&#xD;
&#xD;
          -  At least 2 weeks since prior therapy for multiple myeloma&#xD;
&#xD;
          -  Concurrent growth factors (filgrastim [G-CSF] and epoetin alfa) to sustain peripheral&#xD;
             blood counts (during the first course of therapy only) allowed&#xD;
&#xD;
          -  Concurrent steroid therapy (≤ 20 mg of prednisone) for patients requiring chronic use&#xD;
             for disorders other than myeloma allowed&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent investigational or commercial agents or therapies for this&#xD;
             malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashraf Badros</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland Greenebaum Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201-1595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>March 29, 2006</study_first_submitted>
  <study_first_submitted_qc>March 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2006</study_first_posted>
  <last_update_submitted>February 6, 2013</last_update_submitted>
  <last_update_submitted_qc>February 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

